@article{a96e7f683aff4f33ab358a3db71ad22a,
title = "Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party",
abstract = "The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.",
keywords = "plasmacell leukemia, plasmacell leukemia",
author = "G. D'Arena and Valentini, {C. G.} and G. Pietrantuono and R. Guariglia and Martorelli, {M. C.} and Mansueto, {Giovanna Rosaria} and O. Villani and D. Onofrillo and A. Falcone and G. Specchia and G. Semenzato and {Di Renzo}, N. and L. Mastrullo and A. Venditti and Antonella Venditti and F. Ferrara and Ferdinando Ferrara and A. Palumbo and Livio Pagano and P. Musto",
year = "2012",
doi = "10.1093/annonc/mdr480",
language = "English",
volume = "23",
pages = "1499--1502",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Elsevier Ltd",
}